Table 1.
Patient Characteristics
| Cilostazol 100 mg BID |
Placebo | |
|---|---|---|
| Total number, n | 1116 | 1135 |
| Gender (% male) | 76.3 | 76.4 |
| Age (years) | 65.3 ± 9.2 | 65.9 ± 9.3 |
| Race/ethnicity (%) | 89.2 | 86.2 |
| Body mass index (kg/m2) | 27.2 ± 4.5 | 27.1 ± 4.3 |
| PAD duration | ||
| ≥ 6 months to ≤ 5 years (%) | 59.4 | 62.5 |
| > 5 years (%) | 40.3 | 37.5 |
| Diabetes (%) | 26.4 | 27.3 |
| Hypertension (%) | 62.2 | 63.3 |
| Smoking status | ||
| Never (%) | 8.2 | 8.5 |
| Prior (%) | 53 | 52.5 |
| Current (%) | 38.7 | 38.9 |
| Prior myocardial infarction (%) | 20.6 | 21.2 |
| Prior stroke (%) | 3.9 | 4.9 |
| Prior congestive heart failure (%) | 3.3 | 3.5 |
| Systolic blood pressure (mmHg) | 144.8 ± 20 | 144.5 ± 20 |
| LDL cholesterol (mg/dL) | 136.5 ± 40 | 134.6 ± 40 |
| Ankle-brachial index | 0.64 ± 0.17 | 0.64 ± 0.16 |
| Maximal walking distance @ baseline (meters) | 172.2 | 180.1 |
Data are shown for patients included in the efficacy analysis. Continuous variables are shown as mean ± standard deviation. BID, twice daily. TID, three times a day. There were no statistically significant differences between the groups (all p-values >0.05).